PB2059: SUCCESSFUL OUTCOME OF A PATIENT WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AZACYTIDINE AND AVAPRITINIB: A CASE REPORT

PB2059: SUCCESSFUL OUTCOME OF A PATIENT WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AZACYTIDINE AND AVAPRITINIB: A CASE REPORT

Bibliographic Details
Main Authors:	C. Saha, V. Stables, E. Dimitriadou, J. Schofield, A. Green, D. Radia
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000851068.69737.1a

Similar Items

A case of indolent systemic mastocytosis responding to treatment with Avapritinib
by: Terrence Sun, et al.
Published: (2024-02-01)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
by: A. Reiter, et al.
Published: (2022-06-01)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
by: T. George, et al.
Published: (2022-06-01)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
by: A. Reiter, et al.
Published: (2022-06-01)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
by: A. Reiter, et al.
Published: (2022-06-01)

Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation
by: Lyndsey Sandow, et al.
Published: (2024-01-01)

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
by: Francesco Mannelli, et al.
Published: (2023-10-01)

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
by: Jason Gotlib, et al.
Published: (2023-08-01)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
by: Jason Gotlib, et al.
Published: (2023-08-01)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
by: Emilia Cocorocchio, et al.
Published: (2020-07-01)

Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis
by: Scott Veitch, et al.
Published: (2023-12-01)

Photosensitivity From Avapritinib: Pharamacovigilance Analysis
by: Ajit Venkatakrishnan, et al.
Published: (2022-08-01)

Novel approaches to treating advanced systemic mastocytosis
by: Gilreath JA, et al.
Published: (2019-07-01)

Avapritinib-induced photo-aggravated cutaneous reaction
by: Farinoosh Dadrass, MS, et al.
Published: (2022-03-01)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
by: F. I. Grifoni, et al.
Published: (2022-06-01)

Palpable purpuric eruption mimicking vasculitis following avapritinib
by: Taha Osman Mohammed, BS, et al.
Published: (2022-04-01)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
by: Panagiotis Diamantopoulos, et al.
Published: (2019-05-01)

Pregnancy and Delivery in Patients with Mastocytosis Treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM).
by: Katarzyna Ciach, et al.
Published: (2016-01-01)

TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS
by: Alessandro Buonomo, et al.
Published: (2022-04-01)

PB1998: AZACYTIDINE AND ALLOGENOUS STEM CELL TRANSPLANTATION IN LATE-ONSET ERYTHROPOIETIC PROTOPORPHYRIA
by: Daniel El Fassi, et al.
Published: (2023-08-01)

Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
by: Danielle Almeida Braggio, et al.
Published: (2022-01-01)

Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors
by: Danielle Almeida Braggio, et al.
Published: (2022-01-01)

Mastocytosis
by: Sandra Nora González-Díaz, et al.
Published: (2015-02-01)

Successful treatment of provisional cutaneous mastocytosis with interferon alpha
by: Andrea Rosario, et al.
Published: (2016-01-01)

5-azacytidine for beta-thalassemia?
by: Clegg, J, et al.
Published: (1983)

Azacytidine Treatment for VEXAS Syndrome
by: Marc H. G. P. Raaijmakers, et al.
Published: (2021-12-01)

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
by: A. Teuber, et al.
Published: (2024-01-01)

PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
by: Austin Kulasekararaj, et al.
Published: (2023-08-01)

Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
by: Daria A. Filonenko, et al.
Published: (2021-02-01)

Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine
by: Marco Manzoni, et al.
Published: (2022-05-01)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
by: Lyndsey Sandow, et al.
Published: (2023-01-01)

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment
by: Shuai Ye, et al.
Published: (2021-01-01)

Mastocytosis in Pregnancy
by: Ilknur Col Madendag, et al.
Published: (2010-06-01)

Bullous mastocytosis
by: Nayak Surajit, et al.
Published: (2007-01-01)

Mastocitose Mastocytosis
by: Luciana Cirillo Maluf, et al.
Published: (2009-07-01)

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©
by: Fiona Taylor, et al.
Published: (2021-10-01)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
by: Celine Berthon, et al.
Published: (2020-01-01)

Bullous mastocytosis in an infant treated with the help of narrowband ultraviolet B
by: Parineeta Maria, et al.
Published: (2017-01-01)

A UK Survey Examining the Experience of Adults With Mastocytosis Receiving COVID-19 Vaccination
by: Priya Sriskandarajah, et al.
Published: (2021-11-01)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
by: Muhammad Naim Bin Che Rahimi, et al.
Published: (2023-08-01)